Crude Oil Gains Over 1%; Walgreens Posts Upbeat Earnings

U.S. equities traded higher on Thursday, with the Nasdaq, Dow, and S&P 500 all gaining, while European markets were mostly up and Asian markets mixed. Walgreens Boots Alliance (WBA) reported better-than-expected Q3 earnings and sales, with revenue up 7.2% year-over-year to $38.99 billion and adjusted EPS of 38 cents, but withdrew its 2025 guidance related to an M&A deal. Economic data presented a mixed picture, showing a larger-than-expected Q1 U.S. GDP contraction of 0.5% alongside a significant 16.4% climb in durable goods orders and a decline in initial jobless claims, providing a complex backdrop for market participants.

Analysis

The U.S. market exhibited broad strength, with the Dow, S&P 500, and Nasdaq gaining 0.82%, 0.66%, and 0.69% respectively, despite a backdrop of conflicting economic indicators. A key data point was the downward revision of Q1 U.S. GDP, showing a 0.5% annualized contraction, worse than the previous 0.2% estimate. This was juxtaposed with positive signals including a 16.4% month-over-month surge in durable goods orders and a decline in initial jobless claims to 236,000. In corporate news, Walgreens Boots Alliance (WBA) reported a strong third quarter, with revenue of $38.99 billion (+7.2% YoY) and adjusted EPS of 38 cents both surpassing consensus estimates. However, the company concurrently withdrew its 2025 financial guidance in connection with its M&A deal with Sycamore Partners, introducing significant forward-looking uncertainty. The market saw extreme idiosyncratic moves, with Cyngn (CYN) shares soaring 277% on a partnership with Nvidia and Ascent Solar (ASTI) climbing 113% on a NASA agreement. Conversely, significant shareholder dilution events crushed several stocks, as Globavend Holdings (GVH) and Reviva Pharmaceuticals (RVPH) plummeted 74% and 54% respectively after announcing large share offerings, while Altimmune (ALT) dropped 56% following disappointing clinical trial results.

Key Decisions for Investors

• Despite Walgreens Boots Alliance's (WBA) strong Q3 earnings beat, the withdrawal of its 2025 guidance creates an information vacuum, suggesting investors should temper bullishness until there is more clarity on the post-M&A financial profile.
• The conflicting economic data, featuring a GDP contraction alongside robust durable goods orders, indicates a complex macroeconomic environment; investors should therefore remain cautious about over-exposing portfolios to a single economic outcome and monitor sector rotations, such as the observed strength in Materials over Real Estate.
• The severe price declines in Globavend (GVH), Reviva (RVPH), and Altimmune (ALT) underscore the acute risks of event-driven catalysts, particularly dilutive financing and clinical trial outcomes, reinforcing the need for rigorous due diligence and position sizing in small-cap biotech and newly-listed companies.